(Q46032621)

18 December 2017

title

Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. (English)

1 reference

18 December 2017

1 reference

Christopher G Wood

1

1 reference

18 December 2017

Vitaly Margulis

series ordinal

2

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

18 December 2017

number of pages

6

1 reference

inferred from page(s)

published in

Cancer

1 reference

18 December 2017

volume

115

1 reference

18 December 2017

issue

10 Suppl

1 reference

18 December 2017

page(s)

2355-2360

1 reference

18 December 2017

Surgical management of renal cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Adjuvant therapy for high-risk renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Presurgical therapy in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24240

7 January 2021

Identifiers

DOI

10.1002/CNCR.24240

1 reference

18 December 2017

1 reference

18 December 2017